FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 44 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for... November 6, 2023 FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC December 16, 2022 Cancer in My Community: The 3 Ways People Access Cancer Care... February 2, 2023 Black In Cancer – That Cancer Conversation October 8, 2021 Load more HOT NEWS Best Friends and Owners of a Specialty Cheese Shop Battle Breast... Shorter, More Intensive Radiation Safe after Surgery for Prostate Cancer Coronavirus reports – Part 6 “The kids being home all the... Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function...
